Scholarlink

<p>Despite recent advances in therapy, certain subtypes of colorectal cancer, such as those that are microsatellite instability (MSI-high), mismatch repair deficient (dMMR) or tumor mutation burden high (TMB-H), remain a&#xa0;treatment challenge. In recent years, interest in neoadjuvant therapy strategies for localized colorectal cancer has increased—especially treatment with immunotherapies. At ASCO meeting 2024, updated data on 6‑month course of dostarlimab in patients with dMMR locally advanced rectal cancer as well as several trials investigating the use of neoadjuvant immunotherapy monotherapy or immunotherapy combinations in high-risk stage&#xa0;II–III dMMR colon cancer were presented.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月31日

查看全文
  • Gudrun Piringer

摘要

Despite recent advances in therapy, certain subtypes of colorectal cancer, such as those that are microsatellite instability (MSI-high), mismatch repair deficient (dMMR) or tumor mutation burden high (TMB-H), remain a treatment challenge. In recent years, interest in neoadjuvant therapy strategies for localized colorectal cancer has increased—especially treatment with immunotherapies. At ASCO meeting 2024, updated data on 6‑month course of dostarlimab in patients with dMMR locally advanced rectal cancer as well as several trials investigating the use of neoadjuvant immunotherapy monotherapy or immunotherapy combinations in high-risk stage II–III dMMR colon cancer were presented.